Superworth

Lifevantage price to free cash flow LFVN

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026
11.0×
10-year median
13.4×
Against its 10-year history
34th
percentile: 0 is its lowest day, 100 its highest
10-year range
3.9× to 58.8×
Peer median
12.8×

Lifevantage's price to free cash flow is 11.0× as of Oct 23, 2026.

That is below its ten-year median of 13.4×, lower than on 66% of days in the last ten years.

Over that time it ranged from 3.9× in Apr 2022 to 58.8× in Jan 2025.

The median for 8 large drugmakers of a similar size is 12.8×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far11.0×7.7×41.0×
20258.9×8.9×58.8×
202441.5×6.8×41.5×
20238.1×7.6×57.9×
202211.0×3.9×11.3×
20215.7×5.6×9.3×
20207.5×7.5×24.9×
201924.6×10.5×25.1×
201819.3×11.5×27.9×
201716.6×10.0×45.0×
201621.3×8.6×22.2×
201513.2×5.0×13.2×
201412.7×11.3×18.0×
201315.4×14.4×54.5×
201217.3×16.7×24.1×

Against its peers

Companies in Drug Manufacturers - General nearest Lifevantage's size, closest first, today.

CompanyPrice to free cash flow
LFVNLifevantage11.0×
SPROSpero Therapeuticsn/m
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products11.8×
ARVNArvinasn/m
PBYIPuma Biotechnology13.8×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics17.9×
CRMDCorMedix2.4×
Peer median12.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Lifevantage

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.